Andrew T. Templin, PhD
Assistant Professor of Medicine
- Phone
- (317) 983-3350
- Address
-
1210 Waterway Blvd
Indianapolis, IN 46202 - PubMed:
-
Bio
Andrew Templin joined the faculty of the Indiana University School of Medicine in June 2020 and holds positions at the Indiana Biosciences Research Institute and the Roudebush VA Medical Center.
After completing his Bachelor of Science degree at the Indiana University Hutton Honors College, Andrew conducted medical research at the Northwestern University Feinberg School of Medicine. He then pursued Ph.D. training at the IU Department of Cellular and Integrative Physiology and carried out postdoctoral training at the University of Washington Department of Medicine and VA Puget Sound Health Care System. Prior to joining the faculty at IU, Andrew served as Acting Instructor of Medicine at the UW and Research Scientist at the VA Puget Sound.
Dr. Templin’s work has been selected for funding by the National Institutes of Health, the US Department of Veterans Affairs, the American Diabetes Association, the American Chemical Society, and the Showalter Research Trust. His work has been published in Diabetes, Diabetologia, Diabetes Care, the Journal of Biological Chemistry, and Proceedings of the National Academy of Sciences, among others.
Andrew is a native Hoosier who enjoys travel, soccer, the Chicago Cubs, and golden retrievers.
| Year | Degree | Institution |
|---|---|---|
| 2014 | Fellowship | University of Washington |
| 2014 | PhD | Indiana University |
| 2006 | BS | Indiana University |
Dr. Templin’s research focuses on understanding the relationship between beta-cell failure and islet immune responses in both major forms of diabetes. Emphasis is placed on the concept that beta-cell intrinsic properties are drivers of islet inflammation and beta-cell autoimmunity, and that together these promote a cycle of beta-cell cytotoxicity that leads to diabetes. The Templin Lab is particularly interested in mechanisms of inflammatory, lytic beta-cell death and the role of such pathways in promoting islet inflammation and beta-cell loss in diabetes. These lines of research utilize in vitro models of beta-cell demise and in vivo models of islet amyloid formation, islet inflammation, and beta-cell cytotoxicity to examine how beta-cells themselves promote islet inflammation in the pathogenesis of diabetes. Through this work, the Templin Lab aims to advance our understanding of beta-cell failure in diabetes and improve the health of individuals afflicted with this disease.